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Gene amplifications and deletions frequently contribute to
tumorigenesis. Characterization of these DNA copy-number
changes is important for both the basic understanding of can-
cer and its diagnosis. Comparative genomic hybridization (CGH)
was developed to survey DNA copy-number variations across a
whole genome1. With CGH, differentially labelled test and ref-
erence genomic DNAs are co-hybridized to normal metaphase
chromosomes, and fluorescence ratios along the length of chro-
mosomes provide a cytogenetic representation of DNA copy-
number variation. CGH, however, has a limited (∼20 Mb)
mapping resolution, and higher-resolution techniques, such as
fluorescence in situ hybridization (FISH), are prohibitively
labour-intensive on a genomic scale. Array-based CGH, in which
fluorescence ratios at arrayed DNA elements provide a locus-
by-locus measure of DNA copy-number variation, represents
another means of achieving increased mapping resolution2–4.
Published array CGH methods have relied on large genomic
clone (for example BAC) array targets and have covered only a
small fraction of the human genome. cDNAs representing over
30,000 radiation-hybrid (RH)–mapped human genes5,6 provide
an alternative and readily available genomic resource for map-
ping DNA copy-number changes. Although cDNA microarrays
have been used extensively to characterize variation in human
gene expression7–9, human genomic DNA is a far more complex
mixture than the mRNA representation of human cells. There-
fore, analysis of DNA copy-number variation using cDNA
microarrays would require a sensitivity of detection an order of
magnitude greater than has been routinely reported7. We
describe here a cDNA microarray-based CGH method, and its
application to DNA copy-number variation analysis in breast
cancer cell lines and tumours. Using this assay, we were able to
identify gene amplifications and deletions genome-wide and
with high resolution, and compare alterations in DNA copy
number and gene expression.
We first tested the feasibility of cDNA microarray-based CGH
(Fig. 1a) by analysing genomic DNAs from tumour cell lines with
known gene amplifications or deletions. BT474 is a human breast
cancer cell line in which ERBB2 is amplified10. We labelled
genomic DNA from BT474 cells and genomic DNA from normal
female human leukocytes with Cy5 (pseudocoloured red) and
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Fig. 1 cDNA microarray analysis of DNA copy-number changes. a, Schematic depiction of the
procedure used to measure DNA copy-number changes by cDNA microarray hybridization.
Genomic DNA samples isolated from tumour cells and normal blood leukocytes are labelled
with two different fluorophores (Cy5 and Cy3, respectively) and hybridized together to a sin-
gle cDNA microarray, which is imaged by fluorescence confocal microscopy. For each cDNA
element on the array, the ratio of intensity of the fluorescence measured for the two fluors
represents the relative DNA copy number of that gene in the two samples. The image shown
is produced by superimposing the Cy3 fluorescence image (pseudocoloured green) and the
Cy5 fluorescence image (pseudocoloured red). Thus, red colour represents increased DNA
copy number, green represents decreased DNA copy number (that is, deletion), and yellow
represents no change in DNA copy number in tumour cell DNA compared with normal cell
DNA. In the example shown, amplification of the ERBB2 locus is reflected by the red colour
of the corresponding array element. b, Pseudocolour image of cDNA microarray hybridiza-
tion of BT474 genomic DNA (red) compared with normal female genomic DNA (green).
Inset, an enlarged portion of the array containing ERBB2 cDNA as well as EST IMAGE68400.
c, Spot images from 4 individual cDNA elements (ERBB2, MYC, TP53 and DAZ) are shown
from each of 4 separate experiments that were carried out with ∼5,000-gene microarrays:
BT474 versus normal female, COLO320 versus normal female, NCI-H358 versus normal male
and normal female (XX) versus normal male (XY). Selected red/green fluorescence ratios are
indicated, and represent average ratios for multiple independent elements representing the
same gene on the array. Note that the Y-chromosomal DAZ spots are barely detectable in
the COLO320 and BT474 experiments; this is expected because normal female genomic DNA
was used as the reference for these tumour cell lines.
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Cy3 (pseudocoloured green), respectively, and co-hybridized the
labelled DNAs to a cDNA microarray containing approximately
5,000 human genes. Following hybridization, we scanned the
microarray to produce a pseudocolour image (Fig. 1b). The aver-
age red/green fluorescence ratio of 4 independent cDNA ele-
ments representing ERBB2 on the array was 8.5 (Fig. 1c and
Table 1), closely approximating (but slightly underestimating)
the 10–15:1 ratio determined by Southern-blot analysis (ref. 11,
and data not shown). Similar analyses demonstrated our ability
to detect high-level amplification of MYC, homozygous deletion
of TP53, ‘deletion’ of the Y-chromosomal gene DAZ in a
comparison of male and female genomic DNA, and single-copy
‘deletion’ of the X-chromosomal genes F8C and MCF2 in a com-
parison of normal female with Turner syndrome genomic DNAs
(Fig. 1c and Table 1).
To define the performance of the assay quantitatively, we
hybridized genomic DNAs from cell lines containing varying
numbers of X chromosomes to simulate varying levels of gene
amplification and deletion for each of the 160 X-chromosomal
genes present on the approximately 5,000-gene array. When we
compared two samples of normal female genomic DNA (Fig. 2a),
the red/green fluorescence ratios measured for both autosomal
and X-chromosomal genes were tightly distributed around a
mean value of 1. In contrast, when we compared genomic DNA
Table 1 • cDNA microarray analysis of model DNA copy-number variation
Mean fluorescence Mean fluorescence Test/reference DNA
ratio (±1s.d.)a ratio (±1s.d.)a copy-number ratio
Test DNA Reference DNA Gene element selected gene elementb all ∼5,000 array elements selected gene element
BT474 normal female ERBB2 8.5 (6.9–11) n=4 1.0 (0.76–1.4) 10–15c
COLO320 normal female MYC 31 (28–35) n=4 1.0 (0.81–1.3) 30–50d
NCI-H358 normal male TP53 0.39 (0.29–0.52) n=4 1.0 (0.78–1.3) 0e
TP53∆Aluf 0.06 (0.05–0.08) n=2
normal female normal male DAZg 0.24 (0.20–0.28) n=2 1.0 (0.91–1.2) 0h
Turner (45,XO) normal female F8Ci 0.54 (0.47–0.63) n=3 1.0 (0.89–1.2) 0.5
MCF2i 0.69 (0.64–0.74) n=3
aFluorescence ratios are reported as test/reference. Selected gene element spot images appear in Fig. 1c. Means and standard deviations were calculated in log
space. bCalculated from multiple (n) independent cDNA elements representing the same gene present on the array. cFold-amplification estimated in the breast
cancer cell line BT474 by Southern-blot analysis (ref. 11, and data not shown). dFold-amplification estimated in the colon cancer cell line COLO320 by Southern-
blot analysis (ref. 28, and data not shown). eTP53 is homozygously deleted in the lung cancer cell line NCI-H358 (ref. 29). fDeletion of the Alu repeat in the 3´ UTR
of the TP53 target improved performance, consistent with incomplete blocking of repetitive sequences during hybridization. Alu repeats are present in the 3´
UTRs of approximately 5% of arrayed cDNAs. gY-chromosomal gene. hThe Y-chromosomal gene DAZ has an autosomal homologue (DAZL, which has ∼90%
nucleotide identity to DAZ, including the 3´ UTR; ref. 30), which will cause overestimation of the DNA copy-number ratio by hybridization. iX-chromosomal gene.
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Fig. 2 Measuring X-chromosomal DNA copy-number
variation. a, Genomic DNA samples from 45,XO, 46,XX,
47,XXX, 48,XXXX and 49,XXXXX cell lines were sepa-
rately labelled with Cy5 (red) and compared with
46,XX DNA labelled with Cy3 (green) using a microar-
ray containing 3,920 autosomal cDNAs (representing
3,725 different genes) and 160 X-chromosomal cDNAs
(∼4%, representing 145 different genes); chromosomal
assignments were determined from FISH or RH map-
ping databases. The graphs show the distribution of
red/green fluorescence ratios for the autosomal cDNAs
(solid line) and X-chromosomal cDNAs (dashed line),
plotted as percentage of cDNAs on the ordinate versus
red/green fluorescence ratio (binned by intervals of
0.2, upper boundary of bin indicated) on the abscissa.
The leftward tailing in the distribution of X-chromoso-
mal fluorescence ratios in the bottom panels is due in
part to a small number of cDNAs that have been incor-
rectly assigned to UniGene clusters mapping to the X
chromosome, or have significant homology to autoso-
mal DNA sequences (data not shown). Insets in the first
and third panels show the corresponding profiles
determined using a moving average of fluorescence
ratios, calculated for sets of three adjacent genes
along the chromosome (as determined by RH map
position). b, Plot of mean (±1s.d.) fluorescence ratios of
autosomal cDNAs (black circles) and X-chromosomal
cDNAs (grey diamonds) from each experiment against
number of X chromosomes. Mean (±1s.d.) fluorescence
ratios of X-chromosomal cDNAs were as follows: XO
versus XX, 0.72 (0.59–0.88); XX versus XX, 1.04 (0.93,
1.16); XXX versus XX, 1.31 (1.15–1.50); XXXX versus XX,
1.58 (1.32–1.90); XXXXX versus XX, 1.84 (1.49–2.27).
Lines (solid line for autosomal and dashed line for X-
chromosomal mean fluorescence ratios) were fitted
using standard regression analysis. c, Plot of mean
(±1s.d.) moving average fluorescence ratios of autoso-
mal cDNAs (black circles) and X-chromosomal cDNAs
(grey diamonds) from each experiment against num-
ber of X chromosomes. Moving averages were calcu-
lated as described above.
a b
c
© 1999 Nature America Inc. • http://genetics.nature.com
© 
19
99
 N
at
ur
e 
Am
er
ic
a 
In
c.
 • 
ht
tp
://
ge
ne
tic
s.
na
tu
re
.c
om
letter
nature genetics • volume 23 • september 1999 43
from a 45, XO (Turner syndrome) cell line (red) with normal
female (46, XX) genomic DNA (green), the distribution of fluo-
rescence ratios for X-chromosomal genes was shifted leftward
(mean 0.72; Fig. 2a), reflecting the single-copy loss of X-chromo-
somal genes in the XO sample. Likewise, when we compared
genomic DNAs from 47,XXX 48,XXXX and 49,XXXXX cell lines
(red) with normal female (46, XX) genomic DNA (green), the
distributions of fluorescence ratios for X-chromosomal genes
were shifted rightward (means 1.31, 1.58 and 1.84, respectively;
Fig. 2a), reflecting X-chromosomal DNA copy-number gain. The
mean fluorescence ratios for X-chromosomal genes obtained in
the different experiments fitted tightly to a line (Fig. 2b), with a
regression correlation of 0.99, demonstrating that fluorescence
ratios were linearly proportional to DNA copy number in this
range of low-level gene amplification or single-copy deletion (in
the case of XO versus XX). The slope of the line, 0.28, underesti-
mated the true slope of 0.5, probably due primarily to cross-
hybridization between some X-chromosomal genes and
homologous sequences on autosomes.
Detection of single-copy deletions is important for the identifi-
cation of tumour-suppressor genes. In the comparison of
genomic DNA from an XO cell line with that from normal female
cells, which models single-copy DNA deletion for X-chromoso-
mal genes, we estimate that each individual array element pro-
vided approximately 85% sensitivity (15% false negatives) and
approximately 85% specificity (15% false positives) for detection
of single-copy gene ‘deletion’ (using a decision threshold at the
point where the distributions of fluorescence ratios for autoso-
mal and X-chromosomal genes crossed, at ∼1 s.d. apart from
their means). By using a ‘moving average’ of fluorescence ratios4,
it is possible to increase the accuracy of measurements with little
sacrifice of mapping resolution (because of the large number of
genes arrayed). A moving average analysis, calculated for sets of 3
adjacent genes along the chromosome (determined by RH map
position), increased our estimates of sensitivity and specificity
for detection of single-copy deletion or gain to approximately
98% (the distributions of fluorescence ratios for autosomal and
X-chromosomal genes crossed at ∼2 s.d. apart from their means;
Fig. 2a,c). Note that with the moving average there would be a
loss of sensitivity in detecting regions of amplification and dele-
tion that are small relative to the local density of genes repre-
sented on the array. Of course, the decision thresholds and size of
the moving average window could be adjusted to optimize the
performance characteristics (for example, sensitivity, specificity
and resolution) most desirable for any particular biological
application of the assay.
The cDNA microarrays used in our experiments contained
3,360 cDNAs (representing 3,195 different genes) whose DNA
sequences had been RH-mapped5,6 using the Genebridge4 RH
panel12. In the comparison of BT474 (red) genomic DNA and
Fig. 3 Genome-wide mapping of
DNA copy-number variation for
breast cancer cell line BT474.
a, BT474 DNA copy-number profile
across all chromosomes, derived
from 3360 Genebridge4 RH-mapped
cDNAs (representing 3,195 different
genes) on the microarray depicted
in Fig. 1b. For each chromosome,
red/green fluorescence ratios of
gene spots (ordinate, log10 scale) are
plotted against chromosome map
position as the cR3,000 position
(abscissa) derived from radiation
hybrid mapping using the Gene-
bridge4 RH panel. Fluorescence
ratios greater than one indicate
DNA amplifications; ratios less than
one indicate DNA deletion. Individ-
ual data points across a chromo-
some are connected by lines to
facilitate viewing. Arrows indicate
previously unreported sites of DNA
amplification or deletion confirmed
by quantitative PCR analysis of DNA
copy number. Note, complete DNA
copy-number profiles for normal
female, Turner female (an example
of chromosomal deletion) and
breast cancer cell line MCF7 are
available (http://genome-www.stan-
ford.edu/aCGH/). b, Enlarged view
of chromosome 17 DNA copy-num-
ber profile for BT474, derived from
158 cDNAs (representing 147 differ-
ent genes) RH-mapped (Gene-
bridge4 RH panel) to chromosome
17. The two broad regions of ampli-
fication referred to in the text are
labelled ‘A’ and ‘B’. Inset, the same
profile derived from CGH on
metaphase chromosomes, redrawn
from ref. 15. c, Chromosome 17 DNA
copy-number profile for normal
female genomic DNA. d, Chromo-
some 17 DNA copy-number profiles
for BT474 determined from three
independent experiments. e, Moving average DNA copy-number profiles of chromosome 17 for normal female genomic DNA and BT474. Moving averages were cal-
culated as described in Fig. 2. Complete moving average profiles for normal female genomic DNA and BT474 are available (http://genome-www.stanford.edu/aCGH/).
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normal female (green) genomic DNA (Fig. 1b, pseudocolour
image), we plotted fluorescence ratios for each RH-mapped ele-
ment on the array according to their RH map location in the
genome (Fig. 3a). Known amplifications13 (using conventional
metaphase CGH) along chromosomes 17q and 20q were appar-
ent, as were many previously unreported regions of DNA ampli-
fication and deletion. For example, we observed amplifications
along chromosomes 1q, 8q, 11q and 15q, and deletions along
chromosomes 3p, 6q, 9p, 10q and Xq. These copy-number aber-
rations were confirmed by quantitative PCR (ref. 14) for a single
gene in each region (Fig. 3a, arrows; data available at
http://genome-www.stanford.edu/aCGH/).
An enlarged view of the fluorescence ratio plot for BT474 across
chromosome 17 (Fig. 3b) revealed regions of amplification at
approximately 17q12–q21 (ERBB2 amplicon) and 17q22–q24,
which correspond to the bimodal peak identified15 by metaphase
CGH analysis (Fig. 3b). The cDNA microarray measurements of
DNA copy number were reproducible (Fig. 3d), and displayed
both greater dynamic range and higher resolution than has been
reported for conventional metaphase CGH. The maximum copy-
number ratio measured by cDNA microarray hybridization was
12, compared with less than 2 for the published metaphase
CGH analysis. Moreover, the two regions of amplification
(labelled A and B in Fig. 3b) were more clearly resolved by
cDNA microarray CGH, and the distal 17q amplicon (B) was
itself further resolved into at least two discrete regions of
amplification, revealing a complexity of amplicon structure
in this region previously unappreciated by conventional CGH
and FISH analyses15. With the microarrays used in these
experiments, the mapping resolution was not limited by the
number of genes arrayed, but by the effective resolution of the
RH mapping panel, which at approximately 1 Mb (for the
Genebridge4 RH panel; estimate from http://www.ncbi.nlm.
nih.gov/genemap98/) represents an approximately 20-fold
higher mapping resolution than attainable by metaphase
CGH (ref. 16). The use of moving average ratios (Fig. 3e)
decreased the ‘noisiness’ of the profile with little loss of map-
ping resolution (the shape of the profile was unaltered).
The identification of recurrent regions of DNA amplifi-
cation in tumours has facilitated discovery of oncogenes.
DNA copy-number profiles for chromosomes 17 and 20 are
shown (Fig. 4), generated for three breast tumour cell lines
(BT474, MCF7 and UACC-812) and one primary breast tumour
(BC-2, a poorly differentiated infiltrating ductal carcinoma). We
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chromosome 17 chromosome 20 Fig. 4 High-resolution analysis of recurrent amplicons in breast cancer.
DNA copy-number profiles for chromosomes 17 (derived from 158
cDNAs, representing 147 different genes) and chromosome 20 (derived
from 87 cDNAs, representing 82 different genes) generated for breast
cancer cell lines BT474, MCF7 and UACC-812, and primary breast tumour
BC-2 are depicted. For each sample, red/green fluorescence ratios (ordi-
nate, log10 scale) are plotted against the cR3,000 position derived from
radiation hybrid mapping (abscissa). Individual data points across a chro-
mosome are connected by lines to facilitate viewing. Recurrent regions
of DNA amplification (with greater than fivefold amplification in at least
one of the samples) are highlighted in grey. Selected genes within ampli-
cons are identified. The arrow in the BT474 chromosome 20 profile indi-
cates a region of deletion previously identified by BAC array CGH (ref. 3).
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Fig. 5 Parallel analysis of DNA copy number and gene expression. a, Identical
portion of an ∼5,000-gene microarray. Left, analysis of DNA copy-number vari-
ation in breast carcinoma cell line BT474 (red) compared with normal female
genomic DNA (green). Right, the identical portion of the microarray with gene
expression analysis of the same tumour sample, with BT474 poly(A)+ mRNA
(red) compared with normal human mammary epithelial cell (HMEC) poly(A)+
mRNA (green). Selected genes are identified. b, DNA copy number (ordinate,
log10 scale) is plotted against gene expression (abscissa, log10 scale) for the
∼4,000 mapped genes from the arrays depicted in Fig. 5a. The enclosed region
identifies genes that are both highly amplified (>fivefold) and highly expressed
(>fivefold compared with reference); selected genes are identified.
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identified several recurrent regions of DNA amplification
(Fig. 4). In addition to providing markers for localizing recur-
rent amplicons with high resolution, amplified genes repre-
sented on the array are themselves candidate oncogenes. For
example, the recurrent amplicon at 17q12–q21 (present in
BT474, UACC-812 and BC-2) corresponds to the well-studied
ERBB2 amplicon. In addition to ERBB2, we have detected high
fluorescence ratios for named genes in this amplicon, including
GRB7 (ref. 17) and MLN64/CAB1 (ref. 18), which may con-
tribute to tumour progression17,18, as well as previously unchar-
acterized ESTs (for example EST IMAGE 68400; Fig. 1a, inset).
The region of amplification shared by BT474 and MCF at
approximately 20q12 (Fig. 4) contains the candidate oncogene
AIB1 (refs 19,20), and the region of amplification shared by
BT474 and UACC-812 (∼20q13) contains the candidate onco-
genes TFAP2C (ref. 21) and STK15 (ref. 22). It is notable, how-
ever, that in both of these recurrent chromosome 20 amplicons
the genes that have the highest levels of amplification (and there-
fore presumably the targets of greatest phenotypic selection) are
not the previously recognized candidate oncogenes, but anony-
mous ESTs, suggesting that the relevant oncogenes in these
regions are yet uncharacterized.
The cDNA microarrays used in this study provided an oppor-
tunity to analyse in parallel the changes in DNA copy number
and expression levels of thousands of genes in the same tumour
sample. We compared poly(A)+ mRNA from each of the breast
cancer cell lines and primary tumours (red) with poly(A)+
mRNA prepared from normal human mammary epithelial cells
(green), which, for the purpose of this experiment, served as an
imperfect approximation of the normal counterpart of the
tumour cells. Pseudocolour images from an identical portion of
an array comparing DNA copy-number variation and gene
expression for the BT474 breast cancer cell line are shown
(Fig. 5a). The DNA copy number and gene expression data for
the approximately 4,000 mapped cDNAs on these arrays are also
shown (Fig. 5b). As expected, most highly expressed genes were
not amplified, nor were all amplified genes highly expressed. A
small number of genes were both amplified and highly expressed
(Fig. 5b), and therefore are more likely to include important
mediators of tumour formation or progression. Many of the
genes in the ERBB2 amplicon that were highly amplified in
BT474 cells were also highly expressed (including GRB7, anony-
mous EST IMAGE68400 (Fig. 5b) and MLN64/CAB1), consistent
with the possibility that genes in this region other than ERBB2
may contribute to the tumour phenotype17,18.
There is insufficient data in the literature to comprehensively
compare the performance of our array CGH method with that
of others2–4. When a moving-average ratio is used in our analy-
sis of X-chromosomal copy-number changes, our ability to
detect single-copy deletions/gains appears comparable to that
reported3 using larger BAC array targets. The DNA copy-num-
ber profiles derived from hybridization to cDNA microarrays
appear comparable to those reported using BAC arrays. For
example, the DNA copy-number profile for BT474 across chro-
mosome 20 (Fig. 4), based on the 87 unselected chromosome
20 cDNAs present on our arrays, closely approximates that
obtained3 using 22 BAC targets selected to include loci known
to be amplified. The concordance between the DNA copy-num-
ber profiles includes a region of DNA deletion (Fig. 4, arrow).
The use of cDNA microarrays for analysis of DNA copy-
number variation offers some significant advantages over other
array-based CGH methods2–4, which have relied on array tar-
gets comprised of large genomic DNA clones (for example
BACs, or BAC-derived inter-Alu PCR products). High-density
cDNA microarrays containing 10,000 genes or more are rou-
tinely employed for gene expression analyses (ref. 9, and
unpublished data), but no resource currently exists for full-
genome coverage with large genomic clones. Ultimately, we
would like not only to map DNA copy-number variation at
high resolution, but also to measure changes in DNA copy
number gene by gene, for every human gene. Our results sug-
gest that, using presently available methods and cDNA
resources, the cDNA microarrays can help us attain this goal.
Another important advantage of cDNA microarray-based CGH
is that DNA copy number and gene expression patterns can be
characterized in parallel in the same sample. The ability to
monitor gene amplification and expression in parallel and at
high resolution may facilitate the identification of pathogeneti-
cally important genes in amplicons, and aid in the interpreta-
tion of the gene expression data being collected in studies of
human tumours.
The detection of twofold and smaller differences in DNA
copy number (twofold in XO versus XX, 1.5-fold in XXX versus
XX) is notable. The cDNA elements on our microarrays aver-
aged approximately 1 kb, or about 1.5×10–7 of the mass of the
diploid human genome. Thus, for example, the difference in
copy number of X-chromosomal genes in a comparison of
genomic DNA from a Turner syndrome cell line with that from
normal female cells represents a twofold difference in the par-
tial concentration of a DNA sequence present at one part in six
million in the complex DNA sample. Our ability to detect sin-
gle-copy DNA deletions at the genome level should aid in the
localization and identification of novel tumour-suppressor
genes. Single-copy deletions (and gains) are also a characteristic
feature of many constitutional genetic syndromes, and the
cDNA microarrays may allow mapping and identification of
genes whose copy number is altered in these syndromes. The
ability to scan complex genomes for DNA copy-number varia-
tions using cDNA microarrays should have broad applications
in cancer biology, human genetics, comparative genomics and
other whole-genome studies in a variety of organisms.
Methods
Genomic DNA, mRNA and cell lines. We obtained BT474, COLO320HSR
and NCI-H358 cell lines, and UACC-812 genomic DNA (American Type
Culture Collection). We prepared genomic DNA from cell lines and
peripheral blood using a Blood and Cell Culture DNA Maxi kit (Qiagen).
We obtained genomic DNA samples from 45,XO (repository number
NA01723A), 47,XXX (NA04626), 48,XXXX (NA040695) and 49,XXXXX
(NA06061C) cell lines from the NIGMS Human Genetic Mutant cell
repository. We obtained normal human mammary epithelial cells (Clonet-
ics) and grew them according to the manufacturer’s instructions. We snap
froze primary breast tumours in liquid nitrogen within 20 min of devascu-
larization and stored them at –80 °C. For all cell lines, we isolated poly(A)+
mRNA using a FastTrack 2.0 kit (Invitrogen), whereas for primary breast
tumours, we first isolated total RNA using Trizol reagent (Gibco BRL) fol-
lowed by poly(A)+ mRNA isolation as above.
cDNA microarrays. We fabricated cDNA microarrays essentially as
described23,24. In brief, we PCR-amplified IMAGE (ref. 25) human
cDNAs (ESTs) in 96-well format from DNA minipreps (Qiagen) using
modified M13 universal primers. Most PCR products were 0.5–2 kb. We
suspended purified PCR products in 3×SSC and robotically arrayed them
(spotting ∼1–5 ng each PCR product, 200 µm spacing between spots)
onto polylysine-coated glass microscope slides24. We then processed the
microarrays to immobilize the DNA (ref. 24). The cDNA microarrays
described here contained 5,240 sequence-validated human cDNAs, rep-
resenting 4,915 different human genes (UniGene clusters5,26,27), includ-
ing 5,184 cDNAs of the Research Genetics GeneFilters Release I. Approx-
imately one-half the cDNAs on the microarray were either known genes
or similar to known genes in other organisms, whereas the remainder
were anonymous ESTs.
© 1999 Nature America Inc. • http://genetics.nature.com
© 
19
99
 N
at
ur
e 
Am
er
ic
a 
In
c.
 • 
ht
tp
://
ge
ne
tic
s.
na
tu
re
.c
om
letter
46 nature genetics • volume 23 • september 1999
Labelling and hybridizations. For each labelling, we DpnII-digested (New
England Biolabs) genomic DNA (2 µg), which was then purified (Qiaquick
PCR kit) and random-primer labelled using a Bioprime Labeling kit (Gib-
co BRL), modified to include in a 100 µl reaction, dATP, dGTP and dTTP
(120 µM each), dCTP (60 µM) and Cy5-dCTP or Cy3-dCTP (60 µM). (We
subsequently found that labelling 2 µg of genomic DNA in a 50 µl reaction
volume performed equivalently, and with less reagent cost.) We purified
labelled products using a microcon 30 filter (Amicon). We then combined
Cy5- and Cy3-labelled probes from the entire labelling reactions along with
human Cot-1 DNA (30–50 µg; Gibco BRL), yeast tRNA (100 µg; Gibco
BRL) and poly(dA-dT) (20 µg; Sigma). We concentrated the hybridization
mixture using a microcon 30 filter (Amicon) and adjusted it to contain
3.4×SSC and 0.3% SDS in a 15 µl final volume. Following denaturation
(100 °C, 1.5 min) and a 30 min Cot-1 preannealing step (37 °C), we
hybridized the probe to the array under a glass coverslip at 65 °C for 16–20
h. Following hybridization, we washed the arrays in 2×SSC, 0.03% SDS (65
°C, 5 min), followed by 5 min each at RT in 1×SSC and 0.2×SSC. We
labelled poly(A)+ mRNA for gene expression analysis as described24.
Optimization. During optimization of the cDNA microarray CGH proce-
dure, we found that the labelling efficiency was increased by reducing the
average fragment size of the genomic DNA before random-primed
labelling. This may reflect the increased accessibility of the DNA template
following digestion. We also found it important to add to the hybridization
mixture not only human Cot-1 DNA (to block hybridization to repetitive
elements contained on ∼3% of cDNAs) but also poly(dA-dT) to block non-
specific hybridization to extended poly(A) tails present on some of the
cDNA clones. A small number (∼0.2%) of cDNAs on the array appeared
amplified in most if not all tumour samples tested. Further characteriza-
tion has shown these putative cDNAs to be derived from the mitochondri-
al genome, consistent with previous observations that mitochondria are
typically more abundant in tumour cells than in their normal counter-
parts. The mitochondrial genome-derived clones were identified by
hybridization with purified mitochondrial DNA, allowing them to be
annotated appropriately (data not shown).
Imaging and data analysis. We scanned hybridized arrays by fluorescence
confocal microscopy as described23,24, collecting measurements for each
fluor separately. We calculated fluorescence ratios after background sub-
traction (we calculated background as the median fluorescence signal of
non-target pixels) using the ScanAlyze software package (M.B.E., D.B. and
P.O.B., unpublished data, available at http://rana.stanford.edu/software).
To correct for differences in DNA labelling efficiency between samples, we
then normalized fluorescence ratios across the array to achieve an average
log ratio of 0 (average ratio of 1, that is no DNA copy-number change) for
all cDNA elements on the array. We have corrected ratio values and
pseudocolour array images presented to reflect these normalized ratio val-
ues. We excluded array spots with insufficient fluorescence signal in the
normal genomic DNA sample (fluorescence signal <20% above back-
ground, reflecting PCR or printing failures, <1% of spots), and array spots
with overlying fluorescent debris (manually flagged, <0.5% of spots) from
data analysis. We calculated means and standard deviations of fluorescence
ratios in log space to weight DNA amplifications (fluorescence ratios >1)
and deletions (fluorescence ratios <1) equally. We interpreted DNA copy-
number profiles that deviated significantly (>1s.d.) from background ratio
variations seen in normal genomic DNA samples as evidence of real copy-
number differences4,13. When indicated, we used a ‘moving average’ of flu-
orescence ratios, calculated for sets of three adjacent genes along the chro-
mosome, as determined by RH map position. A moving average ratio
served to average across multiple elements any imprecision in measure-
ment along with inaccuracies due to uncommon RH-mapping/UniGene
misassignments. We obtained RH map positions of cDNAs from the Gen-
eMap’98 RH mapping database12 (database accessible at http://www.ncbi.
nlm.nih.gov/genemap98/), using the UniGene clustering scheme5,26,27 to
assign map positions to cDNA elements on the array.
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